Comment on

• Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

  Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Parving HH, et al. N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121378 Clinical Trial.
• Aliskiren in type 2 diabetes and cardiorenal end points.

  Onuigbo M, Onuigbo N. Onuigbo M, et al. N Engl J Med. 2013 Mar 14;368(11):1064-5. doi: 10.1056/NEJMc1300257. N Engl J Med. 2013. PMID: 23484840 No abstract available.
• Aliskiren in type 2 diabetes and cardiorenal end points.

  Du X, Chen Z, Pan B. Du X, et al. N Engl J Med. 2013 Mar 14;368(11):1065. doi: 10.1056/NEJMc1300257. N Engl J Med. 2013. PMID: 23484841 No abstract available.